There has never been more potential to create an industry centered around patient access, inclusion, and diversity than there is today.  

While traditional approaches have long been responsible for the creation of scientific innovation, barriers continue to have the unintended effect of diminishing access. Today, 70% of potential participants still live more than two hours from a clinical trial site, while others are never made aware of or afforded research opportunities. Studies suggest that the impact of this extends beyond trials themselves, ultimately affecting the efficacy of treatments. For example, the Journal of Asthma reports that 47% of African-American children and 67% of Latin children experience reduced effects from bronchodilators. 

Our industry is more poised than ever to remedy this situation, as it executes novel hybrid, decentralized and patient-centric approaches. In addition, over the last two years, these approaches have resulted in verified data and demonstrated that reliable alternatives exist.


Moderated by Sanskriti Thakur, Chief Growth Officer of Medable, Inc. and previously Head of Global Life Science Research at Accenture, PLC and current member of World Economic Forum Future Council, the webinar will feature leaders at the cutting edge of health innovation:  

  • Dr. Yele Aluko, Chief Medical Officer, EY Americas Business Consulting Health Sector
  • Ken Getz, Director and Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine 
  • Dr. Sapna McManus, Head of Inclusion, Strategy and Partnering, Genentech

The panel will discuss and offer recommendations around the following topics: 

  • What are the necessary changes based on learnings from the global pandemic to improve access and inclusion in scientific research and clinical trials?
  • What are the initiatives in your organization that will demonstrate a marked improvement in population diversity and access improvements?
  • What are the radical proposals you would recommend the industry take to ensure that science is made for every body and biology?
  • What are the long-term impacts of the recent commitment to decentralized clinical trials and the innovation seen by industry such as in: Operation Warpspeed, applications of real-world evidence, FDA and regulatory openness, etc.?
  • What does the word look like from a diversity, equity, and inclusion perspective when this new model decentralized clinical trials (DCT) is the primary choice?